GenFleet Therapeutics (Shanghai) (2595) H2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2025 earnings summary
13 Oct, 2026Executive summary
FY2025 revenue rose 24.4% to RMB130.267m; adjusted loss narrowed 9.3% to RMB226.507m, while reported loss widened to RMB1,794.53m, largely due to fair-value losses on redemption liabilities.
Year-end cash and bank balances reached RMB2,074.80m; GFH375 entered a registrational Phase III trial, while fulzerasib was added to China’s NRDL.
Partial view of Summaries dataset, powered by Quartr API
Latest events from GenFleet Therapeutics (Shanghai)
- GFH375 showed PDAC activity as VS-7375 advanced through early dose escalation.2595
Study update presentation - GFH375 advances across tumor types as GFS202A builds a dual-target cachexia program.2595Investor Day presentation
- GFH375 activity in CCA and CRC, plus GFS202A cachexia signals, supports further study.2595Study result presentation
- GFH375 showed 52.1% confirmed ORR and 8.3-month median PFS in pretreated KRASG12D NSCLC.25952026 World Conference on Lung Cancer presentation
- GFH375 showed 52.1% confirmed ORR in NSCLC, with median PFS of 8.3 months.2595Study result presentation
- GFH375 advanced to Phase III as H1 loss narrowed and cash remained at RMB1.785bn.2595H1 2026
- IPO proceeds of HK$1.67 billion fund an advancing pipeline amid a RMB698.60 million H1 loss.2595H1 2025